Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (FY)Dec 31, 2025 | (Q4)Dec 31, 2025 | (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -870.70%-2.67M | -514.78%-284.81K | -2,787.03%-1.66M | -121.68%-303.64K | -1,132.75%-423.93K | 95.24%-275.13K | 90.08%-46.33K | 96.62%-57.44K | 79.46%-136.97K | 98.83%-34.39K |
| Net income from continuing operations | 42.02%-3.46M | 29.73%-802.6K | 45.48%-2.2M | 50.05%-188.37K | 34.77%-268.98K | 40.04%-5.97M | 53.09%-1.14M | -123.11%-4.04M | 70.61%-377.1K | 90.69%-412.34K |
| Operating gains losses | 490.75%51.09K | 100.93%32.98K | -99.82%6.25K | 92,107.69%11.99K | -108.90%-125 | 92.24%-13.08K | ---3.53M | --3.52M | --13 | --1.4K |
| Asset impairment expenditure | --0 | --0 | ---- | ---- | ---- | --5.07M | 15,912.08%4.6M | ---- | ---- | ---- |
| Unrealized gains and losses of investment securities | -279.84%-22.53K | -126.22%-10K | 318.24%34.8K | -1,134.04%-29K | -150.62%-18.33K | 656.67%12.53K | 1,794.80%38.13K | ---15.95K | ---2.35K | ---7.31K |
| Remuneration paid in stock | 2,282.87%1.27M | --0 | --1.27M | --0 | --0 | -98.50%53.26K | --0 | --0 | --0 | -96.96%53.26K |
| Other non cashItems | -566.22%-223.36K | 61.04%-30.63K | -200,036.36%-197.94K | ---2.51K | --7.72K | -55.98%-33.53K | -127.44%-78.63K | -99.20%99 | ---- | ---- |
| Change In working capital | -146.80%-283.46K | 658.22%525.45K | -6,901.35%-568.93K | -148.49%-95.75K | -143.63%-144.22K | -26.13%605.73K | -85.53%69.3K | -96.48%8.37K | -46.48%197.47K | 224.69%330.6K |
| -Change in receivables | -143.94%-89.94K | -292.16%-42.3K | -911.46%-27.82K | -919.04%-7.65K | -105.72%-12.17K | 562.51%204.67K | -146.94%-10.79K | 107.34%3.43K | 92.77%-751 | 2,195.08%212.78K |
| -Change in prepaid assets | -218.97%-181.24K | 26,872.03%702.08K | -126,217.07%-790.75K | -1,975.30%-74.24K | -112.63%-18.33K | -83.40%152.35K | -99.45%2.6K | -99.47%627 | -98.35%3.96K | 68.66%145.16K |
| -Change in payables and accrued expense | -74.45%63.55K | -175.51%-58.51K | 5,692.06%249.64K | -107.13%-13.85K | -316.01%-113.73K | 564.64%248.71K | 523.91%77.48K | -97.40%4.31K | 38.77%194.26K | 91.98%-27.34K |
| -Change in other working capital | ---75.83K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -870.70%-2.67M | -514.78%-284.81K | -2,787.03%-1.66M | -121.68%-303.64K | -1,132.75%-423.93K | 95.24%-275.13K | 90.08%-46.33K | 96.62%-57.44K | 79.46%-136.97K | 98.83%-34.39K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -180.87%-496.2K | -351.52%-486.33K | -622.29%-31.72K | 522.20%33.46K | 79.52%-11.6K | 90.80%-176.67K | 10.49%-107.71K | 99.49%-4.39K | 93.43%-7.92K | 93.05%-56.64K |
| Capital expenditure reported | -109.39%-369.92K | -170.89%-291.77K | ---- | ---- | ---- | 90.80%-176.67K | 10.49%-107.71K | ---- | ---- | 93.05%-56.64K |
| Net PPE purchase and sale | ---215.1K | ---- | ---- | --0 | --0 | --0 | ---- | ---- | ---7.92K | ---56.64K |
| Net investment purchase and sale | --43.49K | --11.83K | --24.41K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net other investing changes | --45.33K | --8.71K | --22.02K | --26.2K | ---11.6K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -180.87%-496.2K | -351.52%-486.33K | -622.29%-31.72K | 522.20%33.46K | 79.52%-11.6K | 90.80%-176.67K | 10.49%-107.71K | 99.49%-4.39K | 93.43%-7.92K | 93.05%-56.64K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 3,657.25%3.39M | 156.05%74.87K | 4,356.17%2.39M | 194.13%16.7K | 59,648.51%901.61K | -98.44%90.13K | -92.41%29.24K | -98.13%53.71K | -97.90%5.68K | -99.93%1.51K |
| Net issuance payments of debt | --0 | --0 | --0 | --0 | --0 | -84.63%90.13K | --29.24K | -88.57%53.71K | -95.12%5.68K | --1.51K |
| Net common stock issuance | --3.11M | ---10.14K | --2.23M | --0 | --888.3K | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | --280K | --85K | --165K | ---- | ---- | --0 | --0 | --0 | --0 | --0 |
| Net other financing activities | ---- | ---- | ---- | ---- | --13.31K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 3,657.25%3.39M | 156.05%74.87K | 4,356.17%2.39M | 194.13%16.7K | 59,648.51%901.61K | -98.44%90.13K | -92.41%29.24K | -98.13%53.71K | -97.90%5.68K | -99.93%1.51K |
| Net cash flow | ||||||||||
| Beginning cash position | -99.19%2.97K | 619.18%918.87K | 58.62%215.55K | 70.49%469.04K | -99.19%2.97K | -84.01%364.63K | -77.46%127.77K | -47.75%135.89K | -64.62%275.11K | -84.01%364.63K |
| Current changes in cash | 160.73%219.63K | -457.92%-696.27K | 8,758.34%703.32K | -82.08%-253.49K | 620.63%466.07K | 81.12%-361.66K | 38.27%-124.8K | -102.65%-8.12K | 73.10%-139.22K | 94.04%-89.52K |
| End cash Position | 7,397.34%222.6K | 7,397.34%222.6K | 619.18%918.87K | 58.62%215.55K | 70.49%469.04K | -99.19%2.97K | -99.19%2.97K | -77.46%127.77K | -47.75%135.89K | -64.62%275.11K |
| Free cash from | -620.61%-3.26M | -413.96%-791.68K | -2,708.34%-1.74M | -109.56%-303.64K | -365.70%-423.93K | 94.13%-451.79K | 73.77%-154.04K | 98.23%-61.83K | -197.88%-144.9K | 97.58%-91.03K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.